Securities Code: 688690 Securities Abbreviation: Nawei Technology Announcement No.: 2023-015

Suzhou Nawei Technology Co., Ltd.

Announcement on the release of new products by voluntary disclosure companies

the company's board of directors and all directors to ensure that the contents of this announcement does not exist any false records, misleading statements or major omissions, and the authenticity, accuracy and completeness of the contents of the legal responsibility.

Important Content Tips:

Suzhou Nawei Technology Co., Ltd. (hereinafter referred to as the "Company") officially released the Truesynt on March 10, 2023? The first new product of nucleic acid synthesis system-STS0100 oligonucleotide synthesizer system. This product is developed by Suzhou Saipu Instrument Co., Ltd., a holding subsidiary of the company. It is a set of laboratory-level, fully automatic phosphoramidite oligonucleotide synthesizer.

The company is committed to building a complete overall solution from synthesizer, solid phase synthesis carrier, purification equipment, purification packing to analytical chromatographic column to meet the development of nucleic acid drugs to commercial production. The new product STS0100 nucleic acid synthesizer is the company's first product in nucleic acid synthesis, which helps the company to provide more competitive service solutions for biomedical customers and will have a positive impact on the development of the company.

The company's new product STS0100 nucleic acid synthesizer used in nucleic acid drug laboratory-level synthesis link, to achieve large-volume sales still need a long time of marketing and application of technical services investment, there is a future market promotion and customer development less than expected risk.

Basic information of 1. new products

On March 10, 2023, the company officially released the first new product of Truesynt? nucleic acid synthesis system-STS0100 oligonucleotide synthesizer system (hereinafter referred to as "STS0100 nucleic acid synthesizer").

STS0100 nucleic acid synthesizer is developed by Suzhou saipou instrument co., ltd., a subsidiary of the company. it is a laboratory-level, fully automatic phosphoramidite oligonucleotide synthesizer. it can be applied to the synthesis of small nucleic acids such as small interfering nucleic acid (siRNA), microRNA (miRNA), antisense oligonucleotide (ASO), nucleic acid aptamer (Aptamer), etc., with a synthesis range of 50 μmol-9mmol. The equipment is driven by a high-precision plunger pump, which accurately controls the reaction speed and contact time. The well-designed flow path can significantly reduce the amount of monomer and reagent, and ensure low-cost, high-efficiency and high-quality synthesis results.

STS0100 nucleic acid synthesizer has the following product features:

High-precision system pumps provide excellent flow accuracy and repeatability;

The system pipeline is made of peek material, which is resistant to organic reagents and has good biological compatibility;

Smaller volume, larger synthesis range;

The system flow path is optimized, the dead volume is small, and the excessive use of monomer and solvent is reduced;

Powerful online monitoring module, real-time online monitoring of UV, conductivity, temperature, pressure and other parameters;

Monomer reagent can be recycled, the synthesis efficiency is higher;

Lower monomer consumption, less waste liquid generation, lower synthesis costs;

The software interface is friendly, the method can be flexibly edited, and the degree of automation is high;

The synthesis process is simple and clear, easy to linear amplification;

Compliance with FDA and other relevant regulatory requirements;

Provide professional technical support and after-sales service, software lifetime free upgrade service.

2. the impact of new products on the company

Small nucleic acid drugs, namely oligonucleotide drugs, are expected to form the third wave of modern new drugs after small molecule drugs and antibody drugs. Key equipment and consumables related to the preparation and purification of nucleic acid drugs have been dominated and monopolized by foreign companies. As nucleic acid drugs are still in the early stage of industry development, the market pattern of some key consumables and equipment has not yet been determined, and there is no inherent scale and system, which is a good time for industry planning and layout.

The company has long adhered to the underlying technological innovation and cross-field cooperation, breaking through the technical problems of accurate preparation of microspheres, and realizing the wide application of high-performance chromatography fillers and chromatography media in antibodies, vaccines, blood products, enzymes, CGT, insulin, peptides/oligonucleotides, antibiotics, production of hormones/interferons, carbohydrates, natural products and contrast agents. In order to better seize the development opportunities of the next generation of new drugs, the company has invested resources in active layout, from synthesizer, solid phase synthesis carrier, purification equipment, purification packing to analytical column to build a complete solution to meet the development of nucleic acid drugs to commercial production.

At present, the company has listed the sale of nucleic acid new drug-related applications products are:

Nucleic acid purification chromatography media/chromatographic packing

Affinity chromatography media NanoGel-dT20

Ion exchange chromatography media NanoQ-30L, NanoQ-15L, NanoQ-10L, UniDEAE-30S, etc.

Polymer reversed-phase chromatography packing UniPS10-300, UniPS40-1000

Silica gel reversed-phase chromatographic packing UniSil10-200 C18

Nucleic Acid Purification System

Chromatographic purification system SCG-P030, SCG-P100

special analytical column for nucleic acid

DNACore NP-Q of strong anion exchange biological separation column

Reversed phase column DNACore 1000 C18

nucleic acid synthesizer

STS0100 nucleic acid synthesizer (this new product)

At present, the new nucleic acid drug-related application products are: nucleic acid synthesis solid-phase synthesis carrier, pilot-grade nucleic acid synthesis instrument.

The new product STS0100 nucleic acid synthesizer is the company's first product in the nucleic acid synthesis link, which enables the company's products to cover the three application links of nucleic acid drug synthesis, separation and purification, and analysis and detection, which will help the company to provide biomedical customers with More competitive service solutions will have a positive impact on the company's development.

3. related risk tips

The company's new product STS0100 nucleic acid synthesizer used in nucleic acid drug laboratory-level synthesis link, to achieve large-volume sales still need a long time of marketing and application of technical services investment, there is a future market promotion and customer development less than expected risk. Investors are advised to pay attention to investment risks and invest rationally.

It is hereby announced.

Board of Directors of Suzhou Nawei Technology Co., Ltd.

13 March 2023